Literature DB >> 12654813

Synthetic peptides identify promiscuous human Th1 cell epitopes of the secreted mycobacterial antigen MPB70.

Raja Al-Attiyah1, Fatema A Shaban, Harald G Wiker, Fredrik Oftung, Abu S Mustafa.   

Abstract

MPB70 is a secreted protein of Mycobacterium bovis and Mycobacterium tuberculosis which stimulates both cellular and humoral immune responses during infection with bovine and human tubercle bacilli. In addition, vaccination with MPB70 has been shown to induce Th1 cell responses and protection in animal models of tuberculosis. The present study was carried out to map the dominant human Th1 cell epitopes of MPB70 in relation to major histocompatibility complex (MHC) class II restriction in healthy subjects showing strong T-cell responses to complex mycobacterial antigens. Peripheral blood mononuclear cells (PBMC) from HLA-DR-typed donors were tested with complex mycobacterial antigens (whole-cell M. tuberculosis and M. tuberculosis culture filtrates), with MPB70 purified from the culture filtrate of M. bovis BCG Tokyo, and with 13 synthetic peptides (25-mers overlapping by 10 residues) covering the sequence of MPB70. The donors that responded to the complex antigens and MPB70 also responded to the cocktail of synthetic MPB70 peptides. Testing of PBMC with individual peptides showed that peptides p5 (amino acids [aa] 61 to 85), p6 (aa 76 to 100), p8 (aa 106 to 130), p12 (aa 166 to 190), and p13 (aa 181 to 193) were most frequently recognized in proliferation and gamma interferon (IFN-gamma) assays. Testing of antigen-specific CD4(+) T-cell lines with the individual peptides of MPB70 confirmed that peptides p8, p12, and p13 contain immunodominant Th1 cell epitopes of MPB70. MHC restriction analysis with HLA-typed donors showed that MPB70 and its immunodominant peptides were presented to T cells promiscuously. The T-cell lines responding to MPB70 and peptides p8, p12, and p13 in IFN-gamma assays mediated antigen-peptide-specific cytotoxic activity against monocytes/macrophages pulsed with the whole-protein antigen or the peptides. In conclusion, the promiscuous recognition of MPB70 and its immunodominant peptide defined epitopes (aa 106 to 130 and 166 to 193) by IFN-gamma-producing Th1 cells supports possible application of this secreted antigen to subunit vaccine design.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654813      PMCID: PMC152036          DOI: 10.1128/IAI.71.4.1953-1960.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  59 in total

1.  Vgamma9/Vdelta2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis.

Authors:  F Dieli; M Troye-Blomberg; J Ivanyi; J J Fournié; M Bonneville; M A Peyrat; G Sireci; A Salerno
Journal:  Eur J Immunol       Date:  2000-05       Impact factor: 5.532

2.  Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10.

Authors:  S M Arend; P Andersen; K E van Meijgaarden; R L Skjot; Y W Subronto; J T van Dissel; T H Ottenhoff
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

3.  Toward the development of diagnostic assays to discriminate between Mycobacterium bovis infection and bacille Calmette-Guérin vaccination in cattle.

Authors:  H M Vordermeier; P J Cockle; A O Whelan; S Rhodes; R G Hewinson
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

4.  Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4(+) T-cell lines.

Authors:  A S Mustafa; F A Shaban; A T Abal; R Al-Attiyah; H G Wiker; K E Lundin; F Oftung; K Huygen
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

5.  Identification of promiscuous epitopes from the Mycobacterial 65-kilodalton heat shock protein recognized by human CD4(+) T cells of the Mycobacterium leprae memory repertoire.

Authors:  A S Mustafa; K E Lundin; R H Meloen; T M Shinnick; F Oftung
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

6.  Specific skin-reactive protein from culture filtrate of Mycobacterium bovis BCG.

Authors:  S Nagai; J Matsumoto; T Nagasuga
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

7.  Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria.

Authors:  B Kampmann; P O Gaora; V A Snewin; M P Gares; D B Young; M Levin
Journal:  J Infect Dis       Date:  2000-08-15       Impact factor: 5.226

8.  T- and B-cell epitopes in the secreted Mycobacterium bovis antigen MPB70 in mice.

Authors:  S Tollefsen; J M Pollock; T Lea; M Harboe; H G Wiker
Journal:  Scand J Immunol       Date:  2003-02       Impact factor: 3.487

9.  High frequencies of circulating IFN-gamma-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease.

Authors:  A A Pathan; K A Wilkinson; R J Wilkinson; M Latif; H McShane; G Pasvol; A V Hill; A Lalvani
Journal:  Eur J Immunol       Date:  2000-09       Impact factor: 5.532

10.  Comparative studies with various substrains of Mycobacterium bovis BCG on the production of an antigenic protein, MPB70.

Authors:  K Miura; S Nagai; M Kinomoto; S Haga; T Tokunaga
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

View more
  13 in total

1.  Three-dimensional structure determines the pattern of CD4+ T-cell epitope dominance in influenza virus hemagglutinin.

Authors:  Samuel J Landry
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

2.  Comparative evaluation of MPT83 (Rv2873) for T helper-1 cell reactivity and identification of HLA-promiscuous peptides in Mycobacterium bovis BCG-vaccinated healthy subjects.

Authors:  Abu S Mustafa
Journal:  Clin Vaccine Immunol       Date:  2011-08-18

3.  Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG.

Authors:  R Al-Attiyah; A S Mustafa
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

4.  In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis.

Authors:  R Al-Attiyah; A S Mustafa; A T Abal; A S M El-Shamy; W Dalemans; Y A W Skeiky
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

5.  Efficient testing of large pools of Mycobacterium tuberculosis RD1 peptides and identification of major antigens and immunodominant peptides recognized by human Th1 cells.

Authors:  Abu S Mustafa; Raja'a Al-Attiyah; Sumaila N M Hanif; Fatema A Shaban
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

6.  Mycobacterial antigen-induced T helper type 1 (Th1) and Th2 reactivity of peripheral blood mononuclear cells from diabetic and non-diabetic tuberculosis patients and Mycobacterium bovis bacilli Calmette-Guérin (BCG)-vaccinated healthy subjects.

Authors:  R J Al-Attiyah; A S Mustafa
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

7.  Cellular immune responses to recombinant Mycobacterium bovis BCG constructs expressing major antigens of region of difference 1 of Mycobacterium tuberculosis.

Authors:  Kholoud Shaban; Hanady A Amoudy; Abu S Mustafa
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

8.  Therapeutic effects of mycobacterial secretory proteins against established asthma in BALB/c mice.

Authors:  Eui-Ryoung Han; Inseon S Choi; Han-Gyu Choi; Hwa-Jung Kim
Journal:  Allergy Asthma Immunol Res       Date:  2012-03-19       Impact factor: 5.764

Review 9.  Function and Potentials of M. tuberculosis Epitopes.

Authors:  Juraj Ivanyi
Journal:  Front Immunol       Date:  2014-03-24       Impact factor: 7.561

10.  Characterization of a cross-reactive, immunodominant and HLA-promiscuous epitope of Mycobacterium tuberculosis-specific major antigenic protein PPE68.

Authors:  Abu S Mustafa
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.